Welcome!

News Feed Item

Bone Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

Bone Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Bone Cancer Global Clinical Trials Review, H1, 2014" provides data on the Bone Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Bone Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Bone Cancer 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Bone Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Bone Cancer 37
Jan 03, 2014: Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Amgen Inc. 48
Clinical Trial Overview of Amgen Inc. 48
Bayer AG 50
Clinical Trial Overview of Bayer AG 50
Takeda Pharmaceutical Company Limited 52
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 52
Merck & Co., Inc. 53
Clinical Trial Overview of Merck & Co., Inc. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
AstraZeneca PLC 55
Clinical Trial Overview of AstraZeneca PLC 55
Eli Lilly and Company 56
Clinical Trial Overview of Eli Lilly and Company 56
Algeta ASA 57
Clinical Trial Overview of Algeta ASA 57
Clinical Trial Overview of Top Institutes / Government 58
National Cancer Institute 58
Clinical Trial Overview of National Cancer Institute 58
Children's Oncology Group 67
Clinical Trial Overview of Children's Oncology Group 67
The University of Texas M. D. Anderson Cancer Center 70
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 70
Memorial Sloan Kettering Cancer Center 72
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 72
Massachusetts General Hospital 74
Clinical Trial Overview of Massachusetts General Hospital 74
European Organization for Research and Treatment of Cancer 75
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 75
Southwest Oncology Group 76
Clinical Trial Overview of Southwest Oncology Group 76
University Health Network 77
Clinical Trial Overview of University Health Network 77
Stanford University 78
Clinical Trial Overview of Stanford University 78
Five Key Clinical Profiles 79
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Disclaimer 182
Source 183

List of Tables

Bone Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Bone Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Bone Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 46
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 48
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 50
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 52
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 53
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 55
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 56
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2014* 57
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 58
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 67
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 70
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 72
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 74
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 75
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 76
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 77
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 78

List of Figures

Bone Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 181

Read the full report:
Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that Interface Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Interface Corporation is a company developing, manufacturing and marketing high quality and wide variety of industrial computers and interface modules such as PCIs and PCI express. For more information, visit http://www.i...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
What is the best strategy for selecting the right offshore company for your business? In his session at 21st Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, will discuss the things to look for - positive and negative - in evaluating your options. He will also discuss how to maximize productivity with your offshore developers. Before you start your search, clearly understand your business needs and how that impacts software choices.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...
SYS-CON Events announced today that Mobile Create USA will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Mobile Create USA Inc. is an MVNO-based business model that uses portable communication devices and cellular-based infrastructure in the development, sales, operation and mobile communications systems incorporating GPS capabi...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, will discuss how data centers of the future will be managed, how th...
There is huge complexity in implementing a successful digital business that requires efficient on-premise and cloud back-end infrastructure, IT and Internet of Things (IoT) data, analytics, Machine Learning, Artificial Intelligence (AI) and Digital Applications. In the data center alone, there are physical and virtual infrastructures, multiple operating systems, multiple applications and new and emerging business and technological paradigms such as cloud computing and XaaS. And then there are pe...
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?